The first indications of whether early coronavirus vaccine candidates are safe and effective won’t be ready until November or December, Dr. Moncef Slaoui, chief adviser to the federal government’s Operation Warp Speed, said Tuesday.
“We’re reasonably pleased with the progress. It’s been really fast, and we expect to have three waves of efficacy readouts over the next several months,” Slaoui said at a vaccine symposium hosted by Johns Hopkins University.
“First wave with the RNA vaccines imminently November/December, a second wave with the non-replicating vectors vaccine In January or February,” he said, adding that the third wave with a protein platform is expected in March or April.
Slaoui said that the expectation is that companies will file for emergency use authorization or full approval of their vaccines following the readouts.